Analysis of Claudin-1 and -4 as potential treatment targets in penile squamous cell carcinoma
Background Penile carcinoma (PC) is a rare malignancy with an adverse prognosis for patients with tumors at advanced stages. Platinum-based chemotherapy still represents the standard of care but offers limited long-term survival benefit, necessitating the exploration of additional therapeutic targets. Claudin-1 and Claudin-4, key components of cellular tight junctions, play a role in the evolution and progression of various tumor types and may play a therapeutic role in PC. Methods In this study, we analyzed the expression and prognostic value of Claudin-1 and Claudin-4 in a multi-institutional international cohort ( n = 193) of patients with PC. Tissue microarrays (TMAs) comprising representative tumor cores from the tumor center, invasive front, lymph node metastases, and normal penile tissue were used. H-scores of Claudin-1 and Claudin-4 were compared across tumor localizations, tumor stages, histologic subtypes, grades and HPV groups. Patient survival was correlated with Claudin-1 and Claudin-4 expression via Kaplan-Meier analysis. Results Claudin-1 was consistently expressed across tumor locations and was expressed in both HPV+ and HPV- tumors. Furthermore, Claudin-1 expression in FRONT samples was moderately correlated with its expression in CENTER samples. No significant differences in Claudin-1 expression were observed between different tumor stages, histologic subtypes and other clinicopathological characteristics. Moderate or strong Claudin-4 expression (H-score ≥ 100) was observed in 13.5% and 11.5% of FRONT and CENTER samples, respectively. The difference in OS between Claudin-4 CENTER expression groups was nominally significant ( p = 0.024) but not after correction for multiple testing (adjusted p = 0.21). Conclusion Claudin-1 and, to a lesser extent, Claudin-4 are expressed in PC and corresponding metastases, supporting further investigation of these proteins as candidate targets in local and advanced PC.
Authors
- August Fiegl (ORCID: https://orcid.org/0009-0009-0633-1728)
- Kerstin Junker (ORCID: https://orcid.org/0000-0002-0873-8128)
- Kristof Bende
- Oybek Khalmurzaev (ORCID: https://orcid.org/0000-0001-7500-1815)
- Cármen Jerónimo (ORCID: https://orcid.org/0000-0003-4186-5345)
- Rui Henrique (ORCID: https://orcid.org/0000-0003-3171-4666)
- Vsevolod Matveev
- Stefan Lohse (ORCID: https://orcid.org/0000-0003-2529-1900)
- Joachim Steffens (ORCID: https://orcid.org/0009-0000-8054-6334)
- João Lobo (ORCID: https://orcid.org/0000-0001-6829-1391)
- Hagen Loertzer
- Rainer Maria Bohle
- Arndt Hartmann
- Heiko Wunderlich
- Carol Imanuel Geppert
- Alexey Pryalukhin
- Michael Stöckle
- Jan Mink
Institutions
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Universitätsklinikum Erlangen (DE)
- Westpfalz Klinikum (DE)
- Universitätsklinikum des Saarlandes (DE)
- Instituto Português de Oncologia Francisco Gentil (PT)
- Sankt-Antonius-Hospital Eschweiler (DE)
- Ministry of Health of the Russian Federation (RU)
- Comprehensive Cancer Center Erlangen (DE)
- Universitätsklinikum Wiener Neustadt (AT)
- Saarland University (DE)
Publication Details
- Journal
- Diagnostic Pathology
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1186/s13000-026-01874-9
- Primary Topic
- Genital Health and Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Universitätsklinikum Erlangen